SCHEMBL30788357

SCHEMBL30788357

CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(N)=O

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TFPI P10646 4/20 0.59
▸ CXCR4 P61073 2/20 0.56
▸ F2 P00734 4/20 0.56
▸ C5AR1 P21730 1/20 0.55
▸ CALCR P30988 4/20 0.55
▸ IL23R Q5VWK5 1/20 0.55
▸ MC4R P32245 2/20 0.54
▸ MC5R P33032 2/20 0.54
▸ MC3R P41968 2/20 0.54
▸ MC1R Q01726 2/20 0.54
▸ HCRTR1 O43613 1/20 0.53
▸ HCRTR2 O43614 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788369 0.98 C5AR1 (0.57) TFPICXCR4C5AR1IL23RMC4R
SCHEMBL30788365 0.98 F2 (0.58) TFPICXCR4F2CALCR
SCHEMBL30788366 0.97 C5AR1 (0.58) TFPICXCR4C5AR1IL23RMC4R
SCHEMBL30788362 0.96 F2 (0.56) TFPICXCR4F2C5AR1IL23R
SCHEMBL30788340 0.96 F2 (0.59) TFPICXCR4F2CALCRHCRTR1
SCHEMBL30788359 0.95 CTSL (0.56) TFPICXCR4F2C5AR1CALCR
SCHEMBL30788343 0.95 F2 (0.57) TFPICXCR4F2CALCRHCRTR1
SCHEMBL30788336 0.95 F2 (0.57) TFPICXCR4F2CALCRHCRTR1
SCHEMBL30788370 0.94 TFPI (0.59) TFPIF2C5AR1CALCRMC4R
SCHEMBL30788360 0.94 F2 (0.55) TFPICXCR4F2C5AR1CALCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-05-02 — — US disclosed
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-04-18 — — US disclosed
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY GLO PHARMA, INC. 2024-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, PLIN3 TFPI 3801/4885CXCR4 3507/4885F2 3370/4885
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY CHRNB1, CHRNG, CHRNA1 TFPI 2394/4885CXCR4 1494/4885F2 2151/4885
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, LIPE TFPI 4016/4885CXCR4 4105/4885F2 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback